Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 From the mouse cage to human therapy: a personal perspective of the emergence of T-bodies/chimeric antigen receptor T cells.

Literature DB >> 25244568

From the mouse cage to human therapy: a personal perspective of the emergence of T-bodies/chimeric antigen receptor T cells.

Zelig Eshhar¹.

Abstract

Entities: Species

Mesh：

Substances：

Year: 2014 PMID： 25244568 PMCID： PMC4174423 DOI： 10.1089/hum.2014.2532

Source DB: PubMed Journal: Hum Gene Ther ISSN： 1043-0342 Impact factor: 5.695

× No keyword cloud information.

32 in total

1. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

Authors: James N Kochenderfer; Mark E Dudley; Steven A Feldman; Wyndham H Wilson; David E Spaner; Irina Maric; Maryalice Stetler-Stevenson; Giao Q Phan; Marybeth S Hughes; Richard M Sherry; James C Yang; Udai S Kammula; Laura Devillier; Robert Carpenter; Debbie-Ann N Nathan; Richard A Morgan; Carolyn Laurencot; Steven A Rosenberg
Journal: Blood Date: 2011-12-08 Impact factor: 22.113

2. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells.

Authors: Dan Blat; Ehud Zigmond; Zoya Alteber; Tova Waks; Zelig Eshhar
Journal: Mol Ther Date: 2014-03-06 Impact factor: 11.454

3. Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression.

Authors: C H J Lamers; J W Gratama; N M C Pouw; S C L Langeveld; B A Van Krimpen; J Kraan; G Stoter; R Debets
Journal: Hum Gene Ther Date: 2005-12 Impact factor: 5.695

4. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product.

Authors: H M Finney; A D Lawson; C R Bebbington; A N Weir
Journal: J Immunol Date: 1998-09-15 Impact factor: 5.422

5. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.

Authors: J S Huston; D Levinson; M Mudgett-Hunter; M S Tai; J Novotný; M N Margolies; R J Ridge; R E Bruccoleri; E Haber; R Crea
Journal: Proc Natl Acad Sci U S A Date: 1988-08 Impact factor: 11.205

6. Chimeric immunoglobulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation.

Authors: J Goverman; S M Gomez; K D Segesman; T Hunkapiller; W E Laug; L Hood
Journal: Cell Date: 1990-03-23 Impact factor: 41.582

7. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors: James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal: Blood Date: 2010-07-28 Impact factor: 22.113

8. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

Authors: G Gross; T Waks; Z Eshhar
Journal: Proc Natl Acad Sci U S A Date: 1989-12 Impact factor: 11.205

9. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.

Authors: Cor Hj Lamers; Stefan Sleijfer; Sabine van Steenbergen; Pascal van Elzakker; Brigitte van Krimpen; Corrien Groot; Arnold Vulto; Michael den Bakker; Egbert Oosterwijk; Reno Debets; Jan W Gratama
Journal: Mol Ther Date: 2013-02-19 Impact factor: 11.454

10. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors: Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal: N Engl J Med Date: 2013-03-25 Impact factor: 91.245

9 in total

1. Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells.

Authors: Yong Chan Kim; Ai-Hong Zhang; Jeongheon Yoon; William E Culp; Jason R Lees; Kai W Wucherpfennig; David W Scott
Journal: J Autoimmun Date: 2018-05-30 Impact factor: 7.094

Review 2. Combination of celecoxib (Celebrex^®) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas.

Authors: Tam Nm Dinh; Alexandra S Onea; Ali R Jazirehi
Journal: Am J Clin Exp Immunol Date: 2017-05-15

3. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57.

Authors: Xuekai Zhu; Shruthi Prasad; Simone Gaedicke; Michael Hettich; Elke Firat; Gabriele Niedermann
Journal: Oncotarget Date: 2015-01-01

9. Overcoming Resistance of Human Non-Hodgkin's Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors.

Authors: Antoni Xavier Torres-Collado; Ali R Jazirehi
Journal: Cancers (Basel) Date: 2018-06-14 Impact factor: 6.639

9 in total

From the mouse cage to human therapy: a personal perspective of the emergence of T-bodies/chimeric antigen receptor T cells.

1. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

2. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells.

3. Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression.

4. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product.

5. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.

6. Chimeric immunoglobulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation.

7. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

8. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

9. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.

10. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

1. Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells.

Review 2. Combination of celecoxib (Celebrex^®) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas.

3. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57.

4. Rapid and efficient transfer of the T cell aging marker CD57 from glioblastoma stem cells to CAR T cells.

Review 5. Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.

Review 6. Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies.

Review 7. Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy.

Review 8. The Evolution of Cancer Immunotherapy.

9. Overcoming Resistance of Human Non-Hodgkin's Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors.

Review 2. Combination of celecoxib (Celebrex®) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas.

Review 5. Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.

Review 6. Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies.

Review 7. Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy.

Review 8. The Evolution of Cancer Immunotherapy.

Review 2. Combination of celecoxib (Celebrex^®) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas.